Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
Spero Therapeutics (NASDAQ:SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, has scheduled its second quarter 2025 financial results conference call and webcast for Tuesday, August 12, 2025, at 4:30 p.m. ET.
During the call, management will present Q2 2025 financial results and provide a business update. Investors can access the call via phone (1-844-825-9789 domestic, 1-412-317-5180 international) using conference ID 10200686, or through the live audio webcast available on Spero's investor relations website.
Spero Therapeutics (NASDAQ:SPRO), un'azienda biofarmaceutica in fase clinica specializzata in malattie rare e trattamenti per infezioni batteriche multiresistenti, ha programmato la sua presentazione dei risultati finanziari del secondo trimestre 2025 tramite conference call e webcast per martedì 12 agosto 2025, alle ore 16:30 ET.
Durante la chiamata, il management presenterà i risultati finanziari del Q2 2025 e fornirà un aggiornamento sull'andamento aziendale. Gli investitori potranno partecipare alla chiamata telefonando al numero 1-844-825-9789 (nazionale) o 1-412-317-5180 (internazionale) utilizzando l'ID conferenza 10200686, oppure seguendo il webcast audio in diretta disponibile sul sito web delle relazioni con gli investitori di Spero.
Spero Therapeutics (NASDAQ:SPRO), una empresa biofarmacéutica en etapa clínica especializada en enfermedades raras y tratamientos para infecciones bacterianas multirresistentes, ha programado su llamada y webcast de resultados financieros del segundo trimestre de 2025 para el martes 12 de agosto de 2025 a las 4:30 p.m. ET.
Durante la llamada, la dirección presentará los resultados financieros del Q2 2025 y ofrecerá una actualización del negocio. Los inversores pueden acceder a la llamada por teléfono (1-844-825-9789 nacional, 1-412-317-5180 internacional) usando el ID de conferencia 10200686, o a través del webcast de audio en vivo disponible en el sitio web de relaciones con inversores de Spero.
Spero Therapeutics (NASDAQ:SPRO)는 희귀 질환 및 다제내성 세균 감염 치료를 전문으로 하는 임상 단계 생명공학 회사로, 2025년 2분기 재무실적 컨퍼런스 콜 및 웹캐스트를 2025년 8월 12일 화요일 오후 4시 30분(동부시간)에 예정했습니다.
콜 동안 경영진은 2025년 2분기 재무실적을 발표하고 사업 현황을 업데이트할 예정입니다. 투자자들은 국내 전화 1-844-825-9789, 국제 전화 1-412-317-5180번으로 컨퍼런스 ID 10200686을 사용해 참여하거나, Spero 투자자 관계 웹사이트에서 실시간 오디오 웹캐스트를 통해 접속할 수 있습니다.
Spero Therapeutics (NASDAQ:SPRO), une société biopharmaceutique en phase clinique spécialisée dans les maladies rares et les traitements des infections bactériennes multirésistantes, a programmé sa conférence téléphonique et webcast des résultats financiers du deuxième trimestre 2025 pour le mardi 12 août 2025 à 16h30 ET.
Lors de cet appel, la direction présentera les résultats financiers du T2 2025 et fournira une mise à jour sur les activités. Les investisseurs peuvent accéder à l'appel par téléphone (1-844-825-9789 pour les États-Unis, 1-412-317-5180 pour l'international) avec l'identifiant de conférence 10200686, ou via le webcast audio en direct disponible sur le site des relations investisseurs de Spero.
Spero Therapeutics (NASDAQ:SPRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Krankheiten und die Behandlung multiresistenter bakterieller Infektionen spezialisiert hat, hat seine Finanzergebnisse für das zweite Quartal 2025 für Dienstag, den 12. August 2025, um 16:30 Uhr ET als Telefonkonferenz und Webcast angesetzt.
Während des Anrufs wird das Management die Finanzergebnisse des zweiten Quartals 2025 vorstellen und ein Unternehmensupdate geben. Investoren können über die Telefonnummer 1-844-825-9789 (national) oder 1-412-317-5180 (international) mit der Konferenz-ID 10200686 teilnehmen oder den Live-Audio-Webcast auf der Investor-Relations-Website von Spero verfolgen.
- None.
- None.
CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Tuesday August 12th, 2025 at 4:30 p.m. ET to report financial results for second quarter 2025 and provide a business update.
To access the call, please dial 1-844-825-9789 (domestic) or 1-412-317-5180 (international) and refer to conference ID 10200686, or click on this link and request a return call with passcode 0605709. The audio webcast can be accessed live on this link and also on the “Investor Relations” page of the Spero Corporate Website at https://www.sperotherapeutics.com/. The archived webcast will also be available on Spero’s website for 30 days following the call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com
Spero Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@sperotherapeutics.com
Spero Media Inquiries:
media@sperotherapeutics.com
FAQ
When is Spero Therapeutics (SPRO) reporting Q2 2025 earnings?
How can investors access Spero Therapeutics Q2 2025 earnings call?
What is Spero Therapeutics' (SPRO) main business focus?
How long will Spero Therapeutics' Q2 2025 earnings webcast be available?
